Table 5.

Univariable and multivariable Cox regression analysis for PFS of patients receiving FAC/FEC first-line chemotherapy for their recurrent disease (advanced cohort)

UnivariableMultivariable
CharacteristicEvents/NHR (95% CI)PEvents/NHR (95% CI)P
Age (at recurrence)
 ≤4519/24117/211
 >45–5526/301.15 (0.64–2.09)0.624/281.74 (0.77–3.93)0.2
 >5518/230.97 (0.51–1.85)0.917/210.85 (0.25–2.88)0.8
Menopausal status (at recurrence)
 Pre37/44133/391
 Post26/330.85 (0.51–1.40)0.525/310.90 (0.35–2.35)0.8
Dominant relapse site
 Soft tissue5/515/51
 Bone8/100.13 (0.04–0.42)<0.0017/90.07 (0.02–0.28)<0.001
 Visceral50/620.18 (0.06–0.48)<0.00146/560.17 (0.05–0.55)0.003
Disease-free interval
 ≤1 year25/26124/251
 >1–3 years28/370.73 (0.42–1.26)0.324/321.06 (0.55–2.04)0.9
 >3 years10/140.65 (0.31–1.36)0.310/130.85 (0.33–2.15)0.7
ER status
 Negative38/43135/401
 Positive25/340.58 (0.35–0.96)0.03623/301.21 (0.56–2.63)0.6
PR status
 Negative45/52142/481
 Positive18/250.69 (0.40–1.20)0.216/220.85 (0.33–2.14)0.7
HER2 status
 Balanced44/55144/541
 Amplified14/161.31 (0.71–2.39)0.414/161.07 (0.52–2.17)0.9
Hormonal consolidation therapy
 No51/53146/481
 Yes12/230.21 (0.11–0.40)<0.00112/220.16 (0.07–0.36)<0.001
mtDNA
 High36/41135/401
 Low27/360.60 (0.36–1.00)0.04823/300.49 (0.27–0.90)0.022
  • NOTE: In the multivariable model, analysis was limited to 70 patients (58 events) with no missing values.